Correspondence 0001564590-23-001567 from MAIA Biotechnology, Inc. (MAIA) (CIK 0001878313) (MAIA)
MAIA Biotechnology, Inc. (MAIA) (CIK 0001878313)
Date: Feb. 7, 2023 · CIK: 0001878313 · Accession: 0001564590-23-001567
AI Filing Summary & Sentiment
File numbers found in text: 333-269606
Letter
maia-corresp.htm
ThinkEquity LLC
17 State Street, 41st Floor
New York, NY 10004
February 7, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
Washington, D.C. 20549
Attention: Jimmy McNamara
RE:
MAIA Biotechnology, Inc.
Registration Statement on Form S-1 (File No. 333-269606)
Request for Acceleration of Effective Date
Requested Date: February 8, 2023
Requested Time: 5:00 p.m. Eastern Time (US)
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), we, as a representative of the several underwriters, hereby join in the request of MAIA Biotechnology, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time (US), on February 8, 2023, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Very truly yours,
THINKEQUITY LLC
Show Raw Text
CORRESP 1 filename1.htm maia-corresp.htm ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 February 7, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Jimmy McNamara RE: MAIA Biotechnology, Inc. Registration Statement on Form S-1 (File No. 333-269606) Request for Acceleration of Effective Date Requested Date: February 8, 2023 Requested Time: 5:00 p.m. Eastern Time (US) Ladies and Gentlemen: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), we, as a representative of the several underwriters, hereby join in the request of MAIA Biotechnology, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time (US), on February 8, 2023, or as soon thereafter as practicable. Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue. Very truly yours, THINKEQUITY LLC By: /s/ Eric Lord Name: Eric Lord Title: Head of Investment Banking